Nextcure Inc (NXTC)

May 29, 2025

NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 - Insider Monkey

May 29, 2025

May 29, 2025

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - The Manila Times

May 29, 2025

May 29, 2025

NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025 - Nasdaq

May 29, 2025

May 29, 2025

First-in-Human Trial: NextCure's Revolutionary Cancer Drug Shows Promise Against 5 Hard-to-Treat Tumors - Stock Titan

May 29, 2025

May 29, 2025

Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews

May 29, 2025

May 23, 2025

Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - Yahoo Finance

May 23, 2025

May 02, 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 02, 2025

May 02, 2025

NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025

May 02, 2025

NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks

May 02, 2025

May 01, 2025

NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus

May 01, 2025

May 01, 2025

NextCure, Inc. SEC 10-Q Report - TradingView

May 01, 2025

May 01, 2025

NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan

May 01, 2025

Apr 28, 2025

NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

Apr 28, 2025

Apr 26, 2025

Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel

Apr 26, 2025

Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025

Apr 11, 2025

It’s Worth A Gamble To Have A Position In Applied Therapeutics Inc (NASDAQ: APLT) At $0.32. - Marketing Sentinel

Apr 11, 2025

Apr 10, 2025

NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks

Apr 10, 2025

Apr 10, 2025

NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Apr 09, 2025

Apr 07, 2025

2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech

Apr 07, 2025

Apr 04, 2025

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 04, 2025

Apr 04, 2025

Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan

Apr 04, 2025

Apr 03, 2025

CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Apr 03, 2025

Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India

Apr 01, 2025

Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia

Apr 01, 2025

Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India

Mar 25, 2025

Mar 20, 2025

ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire

Mar 20, 2025

Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025

Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India

Mar 18, 2025

Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 18, 2025

NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025

Mar 17, 2025

NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia

Mar 17, 2025

Mar 13, 2025

NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025

Mar 10, 2025

2 Net Current Asset Value Stocks to Consider - GuruFocus.com

Mar 10, 2025

Mar 08, 2025

Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN

Mar 08, 2025

Mar 07, 2025

NextCure Reports 2024 Financials and Strategic Progress - TipRanks

Mar 07, 2025

Mar 07, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times

Mar 07, 2025

Mar 06, 2025

NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq

Mar 06, 2025

Mar 06, 2025

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan

Mar 06, 2025

Mar 06, 2025

NextCure Inc. (NXTC) reports earnings - qz.com

Mar 06, 2025

Feb 27, 2025

Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com

Feb 27, 2025

Feb 27, 2025

NextCure stock plunges to 52-week low, hits $0.69 - MSN

Feb 27, 2025